Our Sponsors

  • SCLN ... Take the advantage of Flowing money

    SciClone Pharmaceuticals SCLN going to be crazy tomorrow....



    The best thing what you can do on wednesday morning is to get in SCLN as early as possible and keep a continuous eye on it and sell when you get atleast 20 % profit.

    Don't take much risk if it is opening around 60 % OR more in the green tomorrow morning. If you can buy it in the premarket or as soon as market opens, it would be the best deal for tomorrow. But remember get in as early as possible and get out when you get a decent profit as it will close much lower than the day's high.

    Leave comments if any concerns. I will try to reply.

    So enjoy God Bless. Be Rich.



    SciClone expects to achieve the following significant milestones:

    -- Achieve strong revenue growth and full year profitability in 2009;
    -- Complete enrollment in the second half of 2009 of the phase 2 trial of
    SCV-07 for the delay of onset of severe oral mucositis in patients
    receiving chemoradiation therapy for the treatment of cancer of the head
    and neck;
    -- Complete preclinical studies in the second half of 2009 evaluating the
    treatment regimen for ZADAXIN as an enhancer of H1N1 pandemic flu vaccine;
    -- Initiate in the second half of 2009 the phase 2 trial of SCV-07 for
    HCV;
    -- Report initial results in the first half of 2010 from the phase 2
    trial of RP101 in pancreatic cancer;
    -- Report initial results in the first half of 2010 from the phase 2
    trial of SCV-07 in severe oral mucositis;
    -- Establish a partnership for the Company's phase 3-ready thymalfasin
    product candidate in stage IV melanoma.


    Revenues Increased 59% Compared With the Second Quarter of 2008; Full Year Guidance Increased for Revenues and Earnings

    FOSTER CITY, CA -- (Marketwire) -- 08/04/09 -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results
    for the second quarter of 2009. Revenues for the quarter grew 59% to $22.0 million compared with the same period in 2008. SciClone reported net income of $7.3 million or $0.16 per share on a basic and diluted basis, compared with a net loss of $0.3 million, or $0.01 per share for the same period of last year.

    "We are very pleased with the exceptional results in this quarter, which allow us to increase our revenue and earnings guidance for the full year. These robust financial results, combined with our cost-containing clinical development strategy and focused expense management, are a result of the execution of our corporate strategy. The recent licensing of the oral anti-nausea product, ondansetron RapidFilm(TM), shows further progress with our corporate strategy to broaden our product pipeline for China and Vietnam, where we see strong growth opportunities," said Friedhelm Blobel, Ph.D., SciClone's President and Chief Executive Officer. "Importantly, we are also preparing for the opportunity to develop ZADAXIN® in certain countries as an enhancer of novel H1N1 flu vaccines for immune-compromised populations. This plan entails many uncertainties, therefore we have not reflected additional sales or earnings in our updated 2009 guidance but we are building inventories to address the potential increased demand associated with this difficult healthcare situation."


    About SciClone

    SciClone Pharmaceuticals (NASDAQ: SCLN) is a profit-driven, global biopharmaceutical company with a substantial international business and a product portfolio of novel therapies for cancer and infectious diseases. SciClone is focused on continuing international sales growth, a cost-containing clinical development strategy, and expense management. ZADAXIN (thymalfasin or thymosin alpha 1) is sold in over 30 countries for the treatment of hepatitis B (HBV) and hepatitis C (HCV), certain cancers and as a vaccine adjuvant. SciClone's pipeline of drug candidates includes thymalfasin for stage IV melanoma, for which SciClone has reached agreement with the FDA on the design of a phase 3 trial; RP101 in a phase 2 trial for the treatment of pancreatic cancer; SCV-07 in a phase 2 trial for the delay of onset of severe oral mucositis in patients receiving chemoradiation therapy for the treatment of cancers of the head and neck; SCV-07 with a ready-to-initiate phase 2 trial for the treatment of HCV. SciClone has exclusive commercialization and distribution rights to DC Bead in China, where the product is under regulatory review. The Company also has commercialization and distribution rights to an anti-nausea drug ondansetron RapidFilmTM in China and Vietnam, for which it is seeking regulatory approval. For additional information, please visit www.sciclone.com.

5 comments:

  1. Jay says:

    you are unbelievable. thanks man... i hope every night i will get these tips from you

  1. Jay says:

    today frontier is 40% down. what shall i do? shall i buy some more?

  1. its definitely going to be up atleast 2 more days.
    If you have more capital go for it but half the quantity you bought earlier. today is profiit taking as it rose from 5 cents.

  1. rufus says:

    Hi...I'm new to stocks. May I know whether it's still advisable to purchase SCLN? Is it too late to buy now?

  1. If you will jump in SCLN now, you probably have to wait for long to get enough profit. If you are here to earn money really fast, keep an eye on stocks that are in limelight. If you want to invest and rest, go for SCLN. You will come to know when it comes in limelight.

Leave a Reply

Latest Posts